Does inflammatory activation increase reliance on EPA-derived specialized pro-resolving mediators?

Inflammation is not merely a passive process that fades away; it requires active biochemical resolution. This physiological shutdown is driven by specialized pro-resolving mediators (SPMs) derived from essential fatty acids, particularly eicosapentaenoic acid (EPA).

State-dependent EPA mobilization

• Under resting, homeostatic conditions, EPA is primarily retained as a latent precursor pool within cell membranes and turns over slowly.
• Upon inflammatory activation, the body undergoes a state-dependent metabolic shift, transitioning EPA from stable membrane storage to active mobilization to meet the demand for pro-resolving substrates.

The enzymatic cascade to E-series resolvins

• The conversion of EPA into E-series resolvins (such as RvE1 and RvE2) is mediated by a highly coordinated transcellular enzymatic pathway.
• Initially, vascular endothelial cells oxygenate EPA into the intermediate 18-HEPE via cytochrome P450 monooxygenases or aspirin-acetylated COX-2.
• Recruited leukocytes then take up 18-HEPE. Acute inflammatory activation drives leukocyte recruitment and significantly upregulates the expression and nuclear translocation of 5-lipoxygenase (5-LOX).
• Acting as the rate-limiting bottleneck, 5-LOX converts 18-HEPE into the critical 5-hydroperoxide and 5(6)-epoxide intermediates required to produce RvE1 and RvE2. These resulting E-series resolvins act as potent agents that limit neutrophil-driven tissue damage and accelerate the return to homeostasis.

Bottom line

• Inflammatory activation drives a metabolic shift that mobilizes EPA from membrane stores and accelerates its transcellular enzymatic conversion via Cytochrome P450/COX-2 and 5-LOX pathways into E-series resolvins, which are essential for limiting neutrophil infiltration and resolving active inflammation.